Application of gefitinib combined with fobatinib in preparation of medicine for treating non-small cell lung cancer

The invention provides an application of gefitinib and Fubatinib (also known as TAS-120) in preparation of drugs for treating EGFR mutant non-small cell lung cancer, compared with single use of Gefitinib or single use of Fubatinib, the combined use of Gefitinib and Fubatinib can effectively inhibit cell proliferation of EGFR mutant non-small cell lung cancer, the Gefitinib and Fubatinib have a synergistic effect in the aspect of resisting cell proliferation of EGFR mutant non-small cell lung cancer, and the application of Gefitinib and Fubatinib in preparation of drugs for treating EGFR mutant non-small cell lung cancer can be used for preparing drugs for treating EGFR mutant non-small cell lung cancer in preparation of drugs for treating EGFR mutant non-small cell lung cancer. Meanwhile, the drug resistance of non-small cell lung cancer cells to Gefitinib can be reversed, the sensitivity of the Gefitinib drug-resistant non-small cell lung cancer cells to Gefitinib can be enhanced, activation of pAKT, pERK an